Found: 23
Select item for more details and to access through your institution.
Heat shock protein is a unique marker of growth arrest during macrophage differentiation of HL-60 cells.
- Published in:
- Journal of Cellular Physiology, 1993, v. 156, n. 3, p. 619, doi. 10.1002/jcp.1041560322
- By:
- Publication type:
- Article
Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor.
- Published in:
- PLoS ONE, 2015, v. 10, n. 11, p. 1, doi. 10.1371/journal.pone.0142845
- By:
- Publication type:
- Article
Photo-Activated Psoralen Binds the ErbB2 Catalytic Kinase Domain, Blocking ErbB2 Signaling and Triggering Tumor Cell Apoptosis.
- Published in:
- PLoS ONE, 2014, v. 9, n. 2, p. 1, doi. 10.1371/journal.pone.0088983
- By:
- Publication type:
- Article
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 8, p. 1115, doi. 10.1007/s00262-007-0441-x
- By:
- Publication type:
- Article
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
- Published in:
- Oncogene, 2005, v. 24, n. 41, p. 6213, doi. 10.1038/sj.onc.1208774
- By:
- Publication type:
- Article
Truncated ErbB2 receptor (p95<sup>ErbB2</sup>) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
- Published in:
- Oncogene, 2004, v. 23, n. 3, p. 646, doi. 10.1038/sj.onc.1207166
- By:
- Publication type:
- Article
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
- Published in:
- Oncogene, 2002, v. 21, n. 41, p. 6255, doi. 10.1038/sj.onc.1205794
- By:
- Publication type:
- Article
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.
- Published in:
- Investigational New Drugs, 2005, v. 23, n. 1, p. 39, doi. 10.1023/B:DRUG.0000047104.45929.ea
- By:
- Publication type:
- Article
What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?
- Published in:
- 2011
- By:
- Publication type:
- Report
A reciprocal tensin-3–cten switch mediates EGF-driven mammary cell migration.
- Published in:
- Nature Cell Biology, 2007, v. 9, n. 8, p. 961, doi. 10.1038/ncb1622
- By:
- Publication type:
- Article
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Medical oncologists' perspectives of the Veterans Affairs National Precision Oncology Program.
- Published in:
- PLoS ONE, 2020, v. 15, n. 7, p. 1, doi. 10.1371/journal.pone.0235861
- By:
- Publication type:
- Article
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
- Published in:
- International Journal of Cancer, 2010, v. 126, n. 12, p. 2893, doi. 10.1002/ijc.24995
- By:
- Publication type:
- Article
X-Ray Psoralen Activated Cancer Therapy (X-PACT).
- Published in:
- PLoS ONE, 2016, v. 11, n. 9, p. 1, doi. 10.1371/journal.pone.0162078
- By:
- Publication type:
- Article
Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion.
- Published in:
- 2013
- By:
- Publication type:
- Correction Notice
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].
- Published in:
- 2012
- By:
- Publication type:
- journal article
Sensitization of tumor cells to Fas killing through overexpression of heat-shock transcription factor 1.
- Published in:
- Journal of Cellular Physiology, 2000, v. 183, n. 3, p. 425, doi. 10.1002/(SICI)1097-4652(200006)183:3<425::AID-JCP16>3.0.CO;2-M
- By:
- Publication type:
- Article
Truncation of Sp1 transcription factor by myeloblastin in undifferentiated HL60 cells.
- Published in:
- Journal of Cellular Physiology, 1998, v. 175, n. 2, p. 121, doi. 10.1002/(SICI)1097-4652(199805)175:2<121::AID-JCP1>3.0.CO;2-Q
- By:
- Publication type:
- Article
Activation signals regulate heat shock transcription factor 1 in human B lymphocytes.
- Published in:
- Journal of Cellular Physiology, 1997, v. 170, n. 3, p. 235, doi. 10.1002/(SICI)1097-4652(199703)170:3<235::AID-JCP3>3.0.CO;2-P
- By:
- Publication type:
- Article
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53.
- Published in:
- Science Signaling, 2013, v. 6, n. 274, p. 1, doi. 10.1126/scisignal.2003741
- By:
- Publication type:
- Article